TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology

Go back to TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
(NASDAQ: RNAZ) Delayed: 1.71 +0.05 (3.01%)
Previous Close $1.66    52 Week High $ 
Open $1.62    52 Week Low $ 
Day High $1.76    P/E N/A 
Day Low $1.62    EPS $ 
Volume 5,737